Stereochemical requirements for pseudoirreversible inhibition of opioid mu receptor binding by the 3‐methylfentanyl congeners, RTI‐46144 and its enantiomers: Evidence for different binding domains
- 1 December 1993
- Vol. 15 (4) , 296-306
- https://doi.org/10.1002/syn.890150406
Abstract
Fentanyl and its congeners are of interest not only because of their clinical applications, but also because certain members of this series of opioid analgesics exhibit unique properties, such as acting as pseudoirreversible inhibitors of μ receptor binding, both in vitro and in vivo. Previous studies showed that pretreatment of membranes with (+)‐cis‐3‐methylfentanyl resulted in a lower affinity interaction of [3H]ohmefentanyl with the μ binding site, as well as an increased dissociation rate. The present study was undertaken to determine the stereochemical requirements for pseudoirreversible inhibition of μ receptor binding using the methylfentanyl congeners, (±)‐cis‐N‐[1‐(2hydroxy‐2‐phenylethyl)‐3‐methyl‐4‐piperidyl]‐N‐phenylpropanamide HCI (RTI‐4614‐4) and its four resolved enantiomers. A R configuration of the 2‐hydroxy group was essential for high affinity binding and pseudoirreversible inhibition. The two enantiomers with this configuration, lb (2R, 3R,4S)‐N‐[1‐(2‐hydroxy‐2‐phenylethyl)‐3‐methyl‐4‐piperidyl]N‐phenylpropanamide oxalate) and lc ((2R, 3S,4R)‐N‐[1‐(2‐hydroxy‐2‐phenylethyl)‐3methyl‐4‐piperidyl]‐N‐phenylpropanamide HC1), acted as pseudoirreversible inhibitors of the μ receptor as labeled with [3H ][D‐Ala2‐McPhe4, Gly‐ol5]enkephalin, [3H]fentanyl or [3H]etorphine. RTI‐4614‐4, lb, and 1c decreased the Bmax of [3H][D‐Ala2‐MePhe4, Glyol5]enkephalin binding sites without altering the dissociation rate. These drugs had a lesser effect on steady‐state [3H]fentanyl and [3H]etorphine binding but did produce statistically significant changes in the parameters of the two‐component dissociation model, which accurately described the dissociation of these [3H]ligands. Viewed collectively, these data indicate that the mechanism of the pseudoirreversible inhibition appears to depend on the radioligand used to label the μ receptor. To explain these data, a pseudoallosteric model is proposed that postulates that certain μ ligands bind to different domains of the drug recognition site of the μ receptor and that the prebinding of pseudoirreversible inhibitors to the recognition site changes the domains available to a radioligand, leading to alterations in steady‐state binding levels and dissociation kinetics. © 1993 Wiley‐Liss, Inc. 1 This article is a US government work and as such, is in the public domain in the United States of America.Keywords
This publication has 26 references indexed in Scilit:
- Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that μ ligands are noncompetitive inhibitors of the δcx opioid peptide binding sitePeptides, 1992
- Replacement of lysine‐181 by aspartic acid in the third transmembrane region of endothelin type B receptor reduces its affinity to endothelin peptides and sarafotoxin 6c without affecting G protein couplingJournal of Cellular Biochemistry, 1992
- [3H]1‐[2‐(2‐thienyl)cyclohexyl]piperidine labels two high‐affinity binding sites in human cortex: Further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complexSynapse, 1991
- (+)-Cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: Evidence for pseudoallosteric modulationNeuropharmacology, 1991
- Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependencePeptides, 1991
- RTI-4614-4: An analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sitesLife Sciences, 1991
- The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: Evidence for a novel mechanism of actionLife Sciences, 1990
- Pseudoallosteric modulation by (+)-MK801 of NMDA-coupled phencyclidine binding sitesLife Sciences, 1990
- A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivoNeuropharmacology, 1989
- Homologous N-alkylnorketobemidones. Correlation of receptor binding with analgesic potencyJournal of Medicinal Chemistry, 1975